Single-dose captopril scintigraphy in the diagnosis of renovascular hypertension

G. N. Sfakianakis, J. J. Bourgoignie, D. Jaffe, G. Kyriakides, E. Perez-Stable, R. C. Duncan

Research output: Contribution to journalArticlepeer-review

108 Scopus citations

Abstract

Renal scintigraphy with [(99m)Tc]diethylenetriaminepentaacetic acid (DTPA) and/or sodium-iodine-131-o-iodohippurate (HIP) was performed before and after an oral dose of captopril (50 mg) in 18 patients with renovascular hypertension (RVH) due to renal artery stenosis (RAS) and 18 controls. In every patient with RVH, captopril induced, enhanced or sustained abnormal findings on HIP scintigraphy depending on the degree of RAS. With DTPA scintigraphy, renal function decreased after captopril in ten kidneys with RVH-related RAS and adequate baseline renal function, but this phenomenon was not evident in 11 kidneys with RVH and poor renal function. Captopril did not influence HIP or DTPA studies of kidneys with patent renal arteries (patients after successful renal angioplasty, patients with essential hypertension, contralateral kidneys of patients with unilateral RVH) or ipsilateral kidneys with mild and subcritical (<60%) RAS in patients without hypertension and/or normal renal vein renin activity. When HIP and DTPA scintigraphy were compared in the same patients, HIP demonstrated greater sensitivity and specificity than DTPA, particularly in patients with poor renal function. HIP scintigraphy before and after a single dose of captopril may provide a rapid sensitive and minimally invasive test for screening patients with hypertension.

Original languageEnglish (US)
Pages (from-to)1383-1392
Number of pages10
JournalJournal of Nuclear Medicine
Volume28
Issue number9
StatePublished - Dec 1 1987

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Single-dose captopril scintigraphy in the diagnosis of renovascular hypertension'. Together they form a unique fingerprint.

Cite this